• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Clinical Study of Intravitreal Injection of Anti-VEGF Drugs Combined with Triamcinolone Acetonide in the Treatment of Coats Disease.抗 VEGF 药物联合曲安奈德玻璃体腔注射治疗 Coats 病的临床研究。
Comput Math Methods Med. 2022 Jun 17;2022:9911549. doi: 10.1155/2022/9911549. eCollection 2022.
2
Combination treatment of pediatric coats' disease: a bicenter study in Taiwan.儿童科茨病的联合治疗:台湾的一项双中心研究。
J Pediatr Ophthalmol Strabismus. 2013 Nov-Dec;50(6):356-62. doi: 10.3928/01913913-20131125-02.
3
Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.前瞻性研究曲安奈德与贝伐单抗治疗视网膜中央静脉阻塞继发黄斑水肿。
Retina. 2011 May;31(5):838-45. doi: 10.1097/IAE.0b013e3181f4420d.
4
Comparison of intravitreal injection of bevacizumab and triamcinolone acetonide in the treatment of uveitic macular edema.玻璃体内注射贝伐单抗与曲安奈德治疗葡萄膜炎性黄斑水肿的比较。
Iran J Immunol. 2012 Jun;9(2):136-44.
5
The effect of intravitreal bevacizumab injection as the initial treatment for Coats' disease.玻璃体腔内注射bevacizumab 作为 Coats 病初始治疗的效果。
Graefes Arch Clin Exp Ophthalmol. 2014 Jan;252(1):35-42. doi: 10.1007/s00417-013-2409-1. Epub 2013 Jul 20.
6
The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats' disease.康柏西普或雷珠单抗玻璃体腔内注射联合激光治疗科茨病的疗效
Graefes Arch Clin Exp Ophthalmol. 2018 Jul;256(7):1339-1346. doi: 10.1007/s00417-018-3949-1. Epub 2018 Mar 16.
7
Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion.玻璃体内曲安奈德醋酸酯与贝伐单抗治疗视网膜中央静脉阻塞所致黄斑水肿。
Eye (Lond). 2009 Dec;23(12):2215-22. doi: 10.1038/eye.2008.429.
8
Micropulsed laser photocoagulation and intravitreal triamcinolone acetonide injection for the treatment of retinal angiomatous proliferation.微脉冲激光光凝联合玻璃体内注射曲安奈德治疗视网膜血管瘤样增生
Retina. 2007 Nov-Dec;27(9):1201-4. doi: 10.1097/IAE.0b013e3180ed45a6.
9
Use of intravitreal triamcinolone and bevacizumab in Coats' disease with central macular edema.应用玻璃体内曲安奈德和贝伐单抗治疗伴有中心性黄斑水肿的 Coats 病。
Graefes Arch Clin Exp Ophthalmol. 2011 Jul;249(7):1099-101. doi: 10.1007/s00417-011-1629-5. Epub 2011 Feb 12.
10
Synergistic Effect of Combined Sub-Tenon Triamcinolone and Intravitreal Anti-VEGF Therapy for Uveitic Macular Edema.联合局部曲安奈德和玻璃体内抗 VEGF 治疗葡萄膜炎性黄斑水肿的协同作用。
Drug Des Devel Ther. 2022 Apr 8;16:1055-1066. doi: 10.2147/DDDT.S353251. eCollection 2022.

引用本文的文献

1
Design and Optimization of Solid Lipid Nanoparticles Loaded with Triamcinolone Acetonide.载三氯醋酸曲安奈德固体脂质纳米粒的设计与优化。
Molecules. 2023 Jul 29;28(15):5747. doi: 10.3390/molecules28155747.
2
Retracted: Clinical Study of Intravitreal Injection of Anti-VEGF Drugs Combined with Triamcinolone Acetonide in the Treatment of Coats Disease.撤回:玻璃体内注射抗VEGF药物联合曲安奈德治疗Coats病的临床研究。
Comput Math Methods Med. 2023 Jul 19;2023:9891537. doi: 10.1155/2023/9891537. eCollection 2023.

本文引用的文献

1
[Choroidal neovascularization due to a punctate inner choroidopathy visualized by optical coherence tomography angiography].[通过光学相干断层扫描血管造影术可视化的点状内层脉络膜病变所致脉络膜新生血管]
Ophthalmologe. 2021 Aug;118(8):842-846. doi: 10.1007/s00347-020-01200-8.
2
Differentiating Multifocal Choroiditis and Punctate Inner Choroidopathy: A Cluster Analysis Approach.多灶性脉络膜炎与特发性脉络膜玻璃膜疣的鉴别:聚类分析方法。
Am J Ophthalmol. 2020 May;213:244-251. doi: 10.1016/j.ajo.2020.01.031. Epub 2020 Feb 4.
3
Intraretinal Cystoid Spaces in Regression of Punctate Inner Choroidopathy Lesions.脉络膜点状病变消退时的视网膜内囊样间隙。
Ocul Immunol Inflamm. 2020 Aug 17;28(6):938-946. doi: 10.1080/09273948.2019.1641210. Epub 2019 Aug 15.
4
Long-Term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis with Active Choroidal Neovascularization Managed with Intravitreal Bevacizumab.特发性点状内层脉络膜病变或多灶性脉络膜炎伴脉络膜新生血管活性病变经玻璃体腔内注射贝伐单抗治疗的长期疗效。
Ocul Immunol Inflamm. 2020;28(1):33-38. doi: 10.1080/09273948.2019.1588335. Epub 2019 Apr 17.
5
Punctate Inner Choroidopathy and Choroidal Neovascularization in Korean Patients.韩国患者的点状内层脉络膜病变和脉络膜新生血管。
Ocul Immunol Inflamm. 2020;28(1):14-19. doi: 10.1080/09273948.2018.1489060. Epub 2018 Dec 14.
6
Development of Secondary Choroidal Neovascularization in Focal Choroidal Excavation of Punctate Inner Choroidopathy.特发性脉络膜凹部局限性脉络膜病变的继发脉络膜新生血管的发展。
Ocul Immunol Inflamm. 2020;28(1):20-25. doi: 10.1080/09273948.2018.1540708. Epub 2018 Nov 13.
7
Long-term results of intravitreal bevacizumab and dexamethasone for the treatment of punctate inner choroidopathy associated with choroidal neovascularization: A case series.玻璃体内注射贝伐单抗和地塞米松治疗与脉络膜新生血管相关的点状内层脉络膜病变的长期结果:病例系列
SAGE Open Med Case Rep. 2018 May 6;6:2050313X18772478. doi: 10.1177/2050313X18772478. eCollection 2018.
8
Retinoic acid-loaded alginate microspheres as a slow release drug delivery carrier for intravitreal treatment.载视黄酸海藻酸钠微球作为一种用于眼内治疗的缓控释药物载体。
Biomed Pharmacother. 2018 Jan;97:722-728. doi: 10.1016/j.biopha.2017.10.109. Epub 2017 Nov 6.
9
Risk Factors for Developing Choroidal Neovascular Membrane and Visual Loss in Punctate Inner Choroidopathy.特发性脉络膜凹部病变的脉络膜新生血管膜形成和视力丧失的危险因素。
Ophthalmology. 2018 Feb;125(2):288-294. doi: 10.1016/j.ophtha.2017.09.002. Epub 2017 Oct 6.
10
Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy.康柏西普作为点状内层脉络膜病变继发脉络膜新生血管主要治疗方法的疗效和安全性。
BMC Ophthalmol. 2017 Jun 12;17(1):87. doi: 10.1186/s12886-017-0481-8.

抗 VEGF 药物联合曲安奈德玻璃体腔注射治疗 Coats 病的临床研究。

Clinical Study of Intravitreal Injection of Anti-VEGF Drugs Combined with Triamcinolone Acetonide in the Treatment of Coats Disease.

机构信息

Department of Ophthalmology, Huangmei People's Hospital, 137 Wuzu Dadao, Huangmei Town, Huangmei County, Huanggang City, Hubei Province 435500, China.

Anesthesiology Department, Caidian District People's Hospital of Wuhan, No. 111 Chenggong Avenue, Caidian District, Wuhan City, Hubei Province 430100, China.

出版信息

Comput Math Methods Med. 2022 Jun 17;2022:9911549. doi: 10.1155/2022/9911549. eCollection 2022.

DOI:10.1155/2022/9911549
PMID:35756410
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9232298/
Abstract

OBJECTIVE

To investigate the clinical study of intravitreal injection of anti-VEGF drugs combined with intravitreal injection of tretinoin for the treatment of Coats disease.

METHODS

The medical records of 90 patients (120 eyes) with Coats disease admitted to our hospital from April 2010 to June 2021 were selected as retrospective study subjects and divided into control and treatment groups according to the numerical table method. There were 45 cases and 60 eyes in each group. Among them, intravitreal tretinoin drug was injected into the control group, and anti-VEGF drug was injected into the vitreous sclera of the treatment group on the basis of the control group.

RESULTS

Before treatment, the differences in visual acuity changes between the two groups were not statistically significant ( > 0.05). After treatment, the light perception, manipulation, and indexes of both groups were significantly improved, and the treatment group was significantly better than the control group. This difference was statistically significant ( < 0.05) for statistical study comparison. The effective rate of 95.56% in the treatment group was significantly higher than that of 86.67% in the control group, and the complication rate was significantly lower than that of the control group, with statistically significant differences ( < 0.05).

CONCLUSION

Intravitreal injection of anti-VEGF drugs combined with tretinoin injection can significantly improve the clinical efficacy of patients with Coats disease and improve visual acuity and central retinal thickness, which has certain reference value for the clinical treatment of Coats disease.

摘要

目的

探讨玻璃体腔注射抗 VEGF 药物联合维 A 酸治疗 Coats 病的临床研究。

方法

选取 2010 年 4 月至 2021 年 6 月我院收治的 90 例(120 眼)Coats 病患者的病历资料进行回顾性研究,采用数字表法分为对照组和治疗组,各 45 例 60 眼。对照组给予玻璃体腔内注射维 A 酸药物,治疗组在对照组基础上给予玻璃体腔注射抗 VEGF 药物。

结果

两组治疗前视力变化差异无统计学意义(>0.05)。两组治疗后光感、手动、指数均有明显改善,且治疗组明显优于对照组,差异有统计学意义(<0.05)。治疗组有效率为 95.56%,明显高于对照组的 86.67%,并发症发生率明显低于对照组,差异均有统计学意义(<0.05)。

结论

玻璃体腔注射抗 VEGF 药物联合维 A 酸治疗 Coats 病可显著提高患者的临床疗效,提高视力和中心视网膜厚度,对 Coats 病的临床治疗具有一定的参考价值。